Abstract
We investigated the prevalence of Helicobacter pylori infection in 90 hemodialysis patients and evaluated the efficacy of its eradication. Twenty-one hemodialysis patients were positive for H.pylori infection by measurement of serological antibody against H.pylori immunoglobulin G (IgG). Seven-day triple therapy with lansoprazole (LPZ) at 30 mg/day, clarithromycin (CAM) at 200 mg/day, and amoxicillin (AMPC) at 500 mg/day was administered to 17 H.pylori-positive hemodialysis patients agreeing to H.pylori eradication therapy. Metronidazole (MNZ) at 250 mg/day was administered to 3 hemodialysis patients with resistance to CAM. A total of 16 of the 17 patients (94.1%) were negative for H.pylori infection by measurement of H.pylori stool antigen for assessment of the success of the eradication therapy. Serological antibody against H.pylori IgG level was 24.8±26.4 U/mL before H.pylori eradication therapy and significantly decreased to 13.9±24.3 U/mL 6 months after it (p<0.05). Therefore, in this study, with a dose below half that in the traditional standard triple therapy for H.pylori eradication, side effects were not identified, but a high rate of success of H.pylori eradication was shown.
